Liraglutide Injection
Product Images NDC 0480-3667

View Photos of Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 35 technical images submitted to the FDA as part of the official labeling for Liraglutide (NDC 0480-3667). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Teva Pharmaceuticals Usa, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

→ Carton_2_pens (carton 2 Pens)

→ Carton_3_pens (carton 3 Pens)

→ Figure-1 (figure 1)

→ Figure-2 (figure 2)

→ Figure_3 (figure 3)

→ Figure_4 (figure 4)

→ Figure-5 (figure 5)

→ Pen_image (image 01)

→ Injection-pen (image 22)

→ Needle-example (image 23)

→ Triangle_1 (image 24)

→ Triangle_2 (image 25)

→ Triangle_3 (image 26)

→ Tirangle_4 (image 27)

→ Triangle_5 (image 28)

→ Triangle_6 (image 29)

→ Tirangle_7 (image 30)

→ Triangle_8 (image 31)

→ Image-a (image 32)

→ Image-b (image 33)

→ Image-c (image 34)

→ Image-d (image 35)

→ Image-e (image 36)

→ Image-f (image 37)

→ Image-g (image 38)

→ Image-h (image 39)

→ Image-i (image 40)

→ Image-j (image 41)

→ Image-k (image 42)

→ Image-l (image 43)

→ Image-m (image 44)

→ Image-n (image 45)

→ Image-o (image 46)

→ Image-p (image 47)

→ Image-q (image 48)

FDA Label Image

Carton_2_pens (Carton 2 Pens)

This text provides detailed information about Liraglutide injection, which is administered subcutaneously under the direction of a healthcare professional. It contains 18 mg/3 mL (6 mg/mL) of liraglutide as the active ingredient, along with various inactive ingredients. The medication is available in a prefilled pen, which can deliver different doses. It should be refrigerated and not frozen. The product is not child-resistant, and if the seal is broken, the pharmacist should be contacted. The manufacturer is Teva Pharmaceuticals in the US and Novo Nordisk in Denmark. Each pen is for single-patient use only and should be discarded after 30 days. Additional details include product literature, disposal instructions, and relevant identification codes.*

FDA Label Image

Carton_3_pens (Carton 3 Pens)

This text describes a medication called Liraglutide injection, which is provided in prefilled pens containing 18 mg/3 mL (6 mg/mL). It is for subcutaneous use only and each pen is intended for single-patient use. The medication contains liraglutide 6mg per mL along with inactive ingredients. It is important to refrigerate the pens and not freeze them. After the first use, they should be stored at a temperature not exceeding 86°F (30°C). The product should not be transferred to a syringe, and each pen can deliver multiple doses of 0.6 mg, 1.2 mg, or 1.8 mg. Additionally, it mentions details for contacting Teva Pharmaceuticals and Novo Nordisk A/S for manufacturing information.*

FDA Label Image

Figure-1 (Figure 1)

FDA Label Image

Figure-2 (Figure 2)

This is a graph showing the comparison of ISR (pmol/kg/min), Liraglutide, and Placebo based on plasma glucose levels (mg/dL). The x-axis represents plasma glucose levels ranging from 80 to 220 mg/dL, while the y-axis indicates ISR values in pmol/kg/min. The data points show how ISR changes in response to Liraglutide and Placebo across different plasma glucose concentrations.*

FDA Label Image

Figure_3 (Figure 3)

This text appears to be a numerical data showing doses of Glimepiride, Liraglutide 1.2 mg, and Liraglutide 1.8 mg over a period of time (weeks). The graph probably depicts the medication dosage changes and their effects over time.*

FDA Label Image

Figure_4 (Figure 4)

This text appears to be outlining measurements of Mean HbA (%) over time, with data points for different medications or dosages such as Liraglutide 1.2 mg, Liraglutide 1.8 mg, and Sitagliptin 100 mg. The measurements are taken at various time points ranging from 0 to 26 weeks. This data is likely part of a study or analysis related to managing or monitoring HbA levels in patients. It provides a visual representation of how these medications may impact Mean HbA (%) levels over time.*

FDA Label Image